Artemisinins are a unique class of antimalarial drugs with significant potential for drug repurposing for a wide range of diseases including cancer. Cancer is a leading cause of death globally and the majority of cancer related deaths occur in Low and Middle Income Countries (LMICs) where conventional treatment options are often limited by financial cost. Drug repurposing can significantly shorten new therapeutic discovery pathways, ensuring greater accessibility and affordability globally. Artemisinins have an excellent safety and tolerability profile as well as being affordable for deployment in Low and Middle Class Income Countries at around USD1 per daily dose. Robust, well designed clinical trials of artemisinin drug repurposing are indicated for a variety of different cancers and treatment settings.

青蒿素是一类独特的抗疟药物，具有重新利用药物治疗包括癌症在内的多种疾病的巨大潜力。癌症是全球主要的死亡原因，大多数与癌症相关的死亡发生在低收入和中等收入国家 (LMIC)，在这些国家，传统治疗方案通常受到财务成本的限制。药物再利用可以显着缩短新的治疗发现途径，确保在全球范围内获得更大的可及性和可负担性。青蒿素具有出色的安全性和耐受性，并且在低收入和中等收入国家部署时价格合理，每天剂量约为 1 美元。青蒿素药物再利用的稳健、精心设计的临床试验适用于各种不同的癌症和治疗环境。